

**REPORT DOCUMENTATION PAGE**

*Form Approved*  
OMB No. 0704-0188

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Service Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

**PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ORGANIZATION.**

<b>1. REPORT DATE (DD-MM-YYYY)</b> 08/26/2017		<b>2. REPORT TYPE</b> Poster		<b>3. DATES COVERED (From - To)</b> 08/26/2017-08/31/2017	
<b>4. TITLE AND SUBTITLE</b> Modification of Measures of Acute Kidney Injury to Risk Stratify Combat Casualties				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b>	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
				<b>5d. PROJECT NUMBER</b>	
<b>6. AUTHOR(S)</b> Lt Col Jonathan Sosnov				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> 59th Clinical Research Division 1100 Willford Hall Loop, Bldg 4430 JBSA-Lackland, TX 78236-9908 210-292-7141				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>  17334	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> 59th Clinical Research Division 1100 Willford Hall Loop, Bldg 4430 JBSA-Lackland, TX 78236-9908 210-292-7141				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION/AVAILABILITY STATEMENT</b> Approved for public release. Distribution is unlimited.					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>					
<b>15. SUBJECT TERMS</b>					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b> Clarice Longoria
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>19b. TELEPHONE NUMBER (include area code)</b> 210-292-7141



# Modification of Measures of Acute Kidney Injury to Risk Stratify Combat Casualties

Jonathan Sosnov, MD MSc<sup>1,2</sup>, Jeffrey T. Howard PhD<sup>3</sup>, Kevin Chung MD<sup>2</sup>, Julie Rizzo, MD<sup>3</sup>; Robert Christy, PhD<sup>3</sup>; Ian Stewart MD<sup>4</sup>  
<sup>1</sup>59th MDW, San Antonio, Tx; <sup>2</sup>Department of Medicine, Brook Army Medical Center, San Antonio, Tx; <sup>3</sup>USAISR, San Antonio, Tx; <sup>4</sup>60th MDW, Travis AFB, Ca



## Introduction

- With the need to prepare for potential extended evacuation times from theater of operation due to both changing mission profiles and potential future conflicts, identifying acute kidney injury (AKI) early can help us determine the need for rapidity of evacuation.
- Early identification of AKI can also assist in aeroevacuation priorities for Role III to Role IV facility transfers.
- Creatinine is easily available as point of care testing and as part of serum chemistries in Role I to III, depending on deployment equipment.
- But, creatinine has both false positives and negatives due to being a muscle breakdown product that takes time to reach steady state.
- The Nephrocheck® Test System is an FDA approved device for identifying early AKI within 12 hours of acute cardiovascular or respiratory compromise in an ICU setting.
- We hypothesize that Nephrocheck® can also be used to identify AKI in injured patients in combat casualty, using burn patients as a

## NephroCheck® Test System

Insulin-like Growth Factor-Binding Protein 7  
 Tissue-Inhibitor of Metalloproteinases 2



## Statements

**Funding:** Support and funding for this study was provided by DHP 6.7 D6.7\_15\_15\_J9\_1114 and analysis funding was provided in part by an appointment to the Internship/Research Participation Program at the United States Army Institute of Surgical Research, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and EPA.  
**Disclaimer:** The views expressed are the authors and do not reflect the official view or policy of the Department of Defense or its Components. The voluntary, fully informed consent of the subjects or LAR used in this research was obtained as required by 32 CFR 219 and DODI 3216.02\_AFI 40-402.

## Methods

**Patients:**  
 130 consecutive burn patients admitted to the ICU at the United States Army Institute of Surgical Research, Burn Unit.  
**Inclusion Criteria:** Age 18-65; Foley catheter placed for clinical purposes; Able to provide a fresh urine sample collected within 72 hours of injury  
**Exclusion Criteria:** End-Stage Renal Disease; Anuria; Pregnant

Admission creatinine compared to the admission Nephrocheck® risk score for the combined outcome of death or need for renal replacement therapy.  
 Creatinine followed for 2 additional days. Urine collected at admission measured using the Nephrocheck® twice (once on a centrifuged sample and once on an un-centrifuged sample) to look at need for centrifuge downrange Combined Outcomes (death or need for dialysis by 30 days) determined on chart review Interim Analysis of first 50 patients displayed on poster

**Table 1. Descriptive Statistics N=50**


Variable	Number (%)	Variable	Mean (STD)
Sex		Age	38.7 (12.3)
Female	9 (18.0)	ISS*	4.5 (3-13)
Male	41 (82.0)	TBSA*	15 (6-25)
MCI		Creatinine	1.0 (0.3)
Burn	42 (84.0)	SBP	123.3 (25.5)
Chemical	1 (2.0)	DBP	68.6 (16.3)
Electrical	7 (14.0)	MAP	88.0 (18.6)
Inhalation injury		Heart Rate	96.7 (19.6)
No	36 (72.0)	Resp Rate	18.3 (6.1)
Yes	14 (28.0)	Temp	99.1 (1.7)
RRT		Weight (kg)	87.8 (18.2)
No	44 (88.0)	Height (cm)	173.7 (9.9)
Yes	6 (12.0)	BMI	28.8 (5.4)
Death			
No	48 (96.0)		
Yes	2 (4.0)		
Combined			
No	42 (84.0)		
Yes	8 (16.0)		

\*Median (IQR)


**Table 2. Logistic Regression Results**

Variable	OR (95% CI); p value
Age	0.97 (0.90, 1.05); p=0.49
Sex	
Female	0.12 (0.01, 2.88); p=0.19
Male (ref)	
Creatinine	0.02 (0.01, 0.87); p=0.04
Centrifuged	0.81 (0.41, 1.59); p=0.53
TBSA	0.95 (0.88, 1.03); p=0.25

**Figure 1. Scatterplot Comparing Centrifuge Samples**



**Figure 2. ROC Curve Comparisons**



## Results

- Centrifuged results are similar to non-centrifuged
- Creatinine is primary predictor of outcomes
- Including TBSA and Centrifuged NephroCheck® results only has a mild increase in predictive capabilities
- Only one patient had an increase of creatinine greater than 0.3

## Conclusions

- Centrifuging samples does not significantly change results suggesting that NephroCheck® could be fielded without a centrifuge
- Even with lack of AKI in time period tested, both creatinine and NephroCheck® predicted 30 day outcomes
- Future studies might need to check repeated measures in order to capture an early AKI in burn patients to test operating characteristics of NephroCheck® vs Creatinine
- Creatinine remains as a key factor in prognosis for triage decisions. A better understanding of its dynamics is clearly warranted.

## References

- 1) Stewart JJ, Tilley MA, Cotant CL, et al. Association of AKI with Adverse Outcomes in Burned Military Casualties. Clin J Am Soc Nephrol;7:199-206.
- 2) Stewart JJ, Sosnov JA, Zonies DH, Morrow BD, Oliver JD, Chung KK. Early acute kidney injury in critically ill combat casualties. ASN Renal Week, Philadelphia PA. 12-16 Nov 2014
- 3) Siew ED, Ware LB, Ickzler TA. Biological markers of acute kidney injury. J Am Soc Nephrol;22:810-820